Samsung Bioepis is a leading biopharmaceutical company dedicated to accelerating access to high-quality biological medicines. Since 2012, we have developed a robust portfolio of biosimilars in immunology and oncology. By providing affordable, reliable treatment options backed by real-world evidence, Samsung Bioepis aims to improve patient lives and healthcare sustainability globally.
Early bird registration is open and closes May 2025. Register now
Abstracts deadline Friday 24 April 2026! Submit now
d
h
m
s
